Ferristatin II Efficiently Inhibits SARS-CoV-2 Replication in Vero Cells.
Animals
Biphenyl Compounds
/ pharmacology
Chlorocebus aethiops
Inhibitory Concentration 50
Protein Binding
Protein Domains
Receptors, Transferrin
/ antagonists & inhibitors
SARS-CoV-2
/ drug effects
Sulfones
/ pharmacology
Vero Cells
Virus Internalization
/ drug effects
Virus Replication
/ drug effects
SARS-CoV-2
Vero cells
ferristatin II
receptor-binding domain (RBD)
transferrin receptor 1
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
03 02 2022
03 02 2022
Historique:
received:
31
12
2021
revised:
29
01
2022
accepted:
01
02
2022
entrez:
26
2
2022
pubmed:
27
2
2022
medline:
11
3
2022
Statut:
epublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to have a significant impact on global public health. Multiple mechanisms for SARS-CoV-2 cell entry have been described; however, the role of transferrin receptor 1 (TfR1) in SARS-CoV-2 infection has received little attention. We used ferristatin II to induce the degradation of TfR1 on the surface of Vero cells and to study the consequences of such treatment on the viability of the cells and the replication of SARS-CoV-2. We demonstrated that ferristatin II is non-toxic for Vero cells in concentrations up to 400 µM. According to confocal microscopy data, the distribution of the labeled transferrin and receptor-binding domain (RBD) of Spike protein is significantly affected by the 18h pretreatment with 100 µM ferristatin II in culture medium. The uptake of RBD protein is nearly fully inhibited by ferristatin II treatment, although this protein remains bound on the cell surface. The findings were well confirmed by the significant inhibition of the SARS-CoV-2 infection of Vero cells by ferristatin II with IC
Identifiants
pubmed: 35215911
pii: v14020317
doi: 10.3390/v14020317
pmc: PMC8876212
pii:
doi:
Substances chimiques
Biphenyl Compounds
0
Receptors, Transferrin
0
Sulfones
0
ferristatin II
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Russian Science Foundation
ID : 21-75-30003
Références
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Chem Biol. 2004 Mar;11(3):407-16
pubmed: 15123270
Nat Metab. 2020 Dec;2(12):1391-1400
pubmed: 33244168
J Med Chem. 2020 Nov 12;63(21):12256-12274
pubmed: 32539378
J Virol. 2020 Mar 17;94(7):
pubmed: 31996437
PLoS One. 2013 Jul 23;8(7):e70199
pubmed: 23894616
Int J Mol Sci. 2019 Nov 22;20(23):
pubmed: 31766619
Signal Transduct Target Ther. 2020 Dec 4;5(1):283
pubmed: 33277466
Am J Physiol Gastrointest Liver Physiol. 2015 Jun 15;308(12):G1019-26
pubmed: 25907691
Nat Rev Mol Cell Biol. 2022 Jan;23(1):3-20
pubmed: 34611326
Arch Dermatol. 1984 Nov;120(11):1519-20
pubmed: 6208852
Crit Care. 2020 Jul 13;24(1):422
pubmed: 32660650
Chem Biol. 2008 Jul 21;15(7):647-53
pubmed: 18635001
Lung. 2020 Dec;198(6):867-877
pubmed: 33170317
Curr Protoc Microbiol. 2020 Sep;58(1):e108
pubmed: 32585083
Cell Discov. 2020 Nov 4;6(1):80
pubmed: 33298900
Science. 2020 Nov 13;370(6518):856-860
pubmed: 33082293
Cell Commun Signal. 2018 Oct 20;16(1):69
pubmed: 30342530
Toxicol In Vitro. 1988;2(1):1-6
pubmed: 20702351
Cell Res. 2021 Feb;31(2):126-140
pubmed: 33420426
Biochemistry (Mosc). 2017 Sep;82(9):1073-1078
pubmed: 28988537
Arch Environ Health. 1988 Jul-Aug;43(4):269-72
pubmed: 3415352
Annu Rev Nutr. 2018 Aug 21;38:431-458
pubmed: 29852086
Science. 2020 Nov 13;370(6518):861-865
pubmed: 33082294
Cell. 2004 Apr 30;117(3):285-97
pubmed: 15109490
PLoS Pathog. 2020 Jul 30;16(7):e1008682
pubmed: 32730327
Am J Clin Pathol. 1981 Dec;76(6):810-2
pubmed: 6172035
PLoS One. 2014 May 15;9(5):e97640
pubmed: 24830643
Nature. 2020 May;581(7807):221-224
pubmed: 32225175
Proc Natl Acad Sci U S A. 2013 Jun 25;110(26):10777-82
pubmed: 23754414
Cell Rep. 2021 Jul 13;36(2):109364
pubmed: 34214467
PLoS Pathog. 2021 Jul 12;17(7):e1009706
pubmed: 34252168
J Virol. 2014 May;88(9):5050-61
pubmed: 24554660